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tained high activities of the B/I peak (39 to 80%) comparedEffect of chronic renal failure on bone turnover and bone
with human serum (4%).alkaline phosphatase isoforms.
Conclusion. There are selective differences between theBackground. Biochemical markers of bone turnover are
BALP isoforms in CRF compared with healthy adults. The com-used to monitor metabolic bone disease associated with renal
mercial BALP immunoassays are comparable with each otherfailure. We have applied a comprehensive panel of markers to
but are unable to distinguish the BALP isoform-specific differ-patients with chronic renal failure (CRF), with particular focus
ences in CRF patients.on the isoforms of bone alkaline phosphatase (BALP).
Methods. Twenty CRF patients undergoing hemodialysis
(N  9) and peritoneal dialysis (N  11) were measured for
serum parathyroid hormone (PTH), osteocalcin, total ALP, Renal bone disease, common in chronic renal failure
and four BALP isoforms (B/I, B1x, B1, and B2) by high-perfor-
(CRF), is a multifactoral disorder of bone remodelingmance liquid chromatography. These BALP isoforms were also
encompassing a spectrum of histologically classified dis-compared with BALP measured by three commercial immuno-
orders ranging from high-turnover osteitis fibrosa throughassays (Alkphase-B, Tandem-R Ostase, and Tandem-MP Os-
tase). Type I collagen turnover was assessed by serum samples adynamic osteopathies to low-turnover bone disease [1].
using the type I procollagen intact amino- and carboxy-terminal Accurate classification of the type of renal bone disease
propeptides (PINP and PICP) and two fragments (ICTP and is achieved through bone histomorphometry after iliac
CrossLaps) derived from the carboxy-terminal telopeptide of
crest biopsy. However, less invasive approaches, includ-mature matrix collagen by different degradative pathways.
ing the use of biochemical markers of bone turnover andResults. Mean levels of bone turnover markers were ele-
vated in CRF, with marked increases in those markers, osteo- various skeletal imaging methods such as dual-energy
calcin, ICTP, and CrossLaps, cleared by the kidney. Total ALP x-ray absorptiometry and 18F-fluoride positron emission
activities were increased corresponding to elevated B/I and tomography, are under investigation [2–4].
B2 isoform levels. The B1 isoform level was not significantly Markers of bone turnover such as bone alkaline phos-different from healthy controls. B1x was detected in 60% of
phatase (BALP) and osteocalcin are considered specificthe patients but was not resolved in healthy individuals. Ken-
for osteoblast-related processes [5]. Serum total ALP isdall’s tau rank correlation showed that B1x correlated signifi-
cantly (P  0.05) with B1 (0.53) and PINP (0.55), and was frequently used to monitor bone metabolism in patients
the only marker to correlate with PTH (0.49). B1x was not with renal failure, as ALP is one of the few bone markers
significantly correlated with any of the commercial BALP im- that is not influenced by variations in renal function.
munoassays. Interestingly, the immunoassay calibrators con-
Approximately 95% of the total ALP activity is derived
from bone and liver sources, which occur in a ratio of
approximately 1:1 in serum from healthy adults [6]. Both1 Present address: Musculoskeletal Disease Center (151), Jerry L. Pettis
BALP and liver ALP (LALP) are encoded by the tissueMemorial VA Medical Center, 11201 Benton Street, Loma Linda, CA
92357, USA. nonspecific gene locus and are referred to as isoforms of
the same isoenzyme. BALP functions as an ectoenzymeKey words: renal osteodystrophy, dialysis, biochemical markers, pro-
attached to the osteoblast cell membrane by a hydropho-collagen propeptides, collagen telopeptides, osteocalcin, parathyroid
hormone. bic glycosylphosphatidylinositol (GPI) anchor [7, 8].
BALP has been reported to be necessary for the initia-Received for publication August 31, 2000
tion of mineralization but not for the continuation ofand in revised form January 12, 2001
Accepted for publication February 7, 2001 the process [9–11]; however, the precise function of
BALP has still to be elucidated. 2001 by the International Society of Nephrology
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In this study, we have used a previously described CrossLaps. Both structures are derived from the car-
boxy-terminal telopeptide region of trivalently cross-weak anion-exchange high-performance liquid chroma-
tography (HPLC) method that can resolve at least six linked type I collagen, although the epitope and the
origin of the fragments measured are different. Thedifferent ALP isoforms in serum from healthy adults:
three BALP (B/I, B1, and B2) and three LALP (L1, L2, CrossLaps assay detects cathepsin K generated degrada-
tion products, whereas the ICTP antigenicity is destroyedand L3) isoforms [12, 13]. An additional BALP isoform
(B1x) has recently been observed in human bone tissue by cathepsin K [19]. Serum ICTP is most likely produced
by the action of matrix metalloproteinases.samples and was also found in serum from patients with
CRF [14]. A higher B1x activity was found in trabecular This study was primarily designed to investigate the
BALP isoforms, in particular the B1x isoform, in patientsbone in comparison with cortical bone, which is in line
with the other BALP isoforms. By several different iden- with CRF undergoing dialysis therapy and to compare
these isoforms with commercially available immunoas-tification procedures, B1x was verified to be a soluble
(anchorless) ALP isoform of bone origin circulating in says of BALP. We also assessed some of the most re-
cently developed assays of type I collagen turnover andCRF patients. A possible kidney ALP origin, or intesti-
nal ALP type from human kidney, was also ruled out. their relationships with the BALP isoforms.
B1x has not been observed in healthy individuals or in
any other group of patients. However, the presence of
METHODS
B1x in healthy subjects (and in patients) cannot be ex-
Subjectscluded since its intermediate retention, and possible
lower activity than either of the B/I and B1 peaks, may The study group with CRF was composed of 20 adult
patients, 9 males and 11 females, with a mean age of 63confound its detection [14].
In healthy adults, the three BALP isoforms, B/I, B1, years (range 33 to 87 years). All were on chronic dialysis
therapy: hemodialysis (N  9; 5 males and 4 females),and B2, account on average for 4, 16, and 37%, respec-
tively, of the total serum ALP activity [14]. In serum, with a median (range) disease duration of 9 (4 to 26)
years and treatment duration of 23 (4 to 126) months,the minor fraction B/I is not a pure BALP isoform,
as it coelutes with intestinal ALP and is composed, on or peritoneal dialysis (N  11; 4 males and 7 females),
with a disease duration of 13 (1 to 27) years and a treat-average, of bone (70%) and intestinal (30%) ALP. Both
of the two major BALP isoforms found in serum, B1 ment duration of 13 (5 to 89) months. Underlying ne-
phropathy types were 10 with chronic glomerulonephri-and B2, are soluble, as they have no remaining fragments
of the in situ GPI cell membrane anchor, and the differ- tis, 4 with diabetic nephropathy, 2 with nephrosclerosis,
1 with chronic tubulointerstitial nephropathy, and 3 ofences are likely due to different glycosylation patterns
[14]. We have recently reported that cortical bone has unknown origin. All patients were treated with calcium
carbonate (phosphate binder) and alphacalcidol (vita-approximately twofold higher activity of B1 compared
with B2, and conversely, the B2 activity is approximately min D analogue). None were treated with corticoste-
roids, and no patients received aluminum-containingtwofold higher in trabecular bone compared with B1
[14]. Selective differences between these BALP isoforms phosphate binders. For both peritoneal and hemodialy-
sis, the dialysate calcium concentration was 1.75 mmol/L.have previously been described in several disease states
including the following: growth hormone deficiency [6], All blood samples were drawn predialysis, and no sig-
nificant differences were found between those patientshypophosphatasia, hypophosphatemic vitamin D-resis-
tant rickets, stress fractures [12, 15], metastatic bone on peritoneal and hemodialysis therapy with respect to
age, disease duration, or dialysis duration.disease [16], Paget’s disease [abstract; Sharp et al, J Bone
Miner Res 14(Suppl 1):S540, 1999], and during the puber- The control group for serum BALP isoforms was com-
posed of 153 healthy adults, 45 males and 108 females,tal growth spurt [17].
We also investigated serum osteocalcin and several with a mean age of 46 years (range 21 to 90 years), and
the control group for serum osteocalcin was composedmarkers of collagen turnover. De novo collagen forma-
tion was assessed by measuring both the intact amino- of 1121 healthy adults, 190 males and 931 females, with
a mean age of 53 years (range 25 to 90 years). This studyand carboxy-terminal propeptides of type I procollagen
(PINP and PICP). Extracellular cleavage of these allows was conducted in accordance with the Declaration of
Helsinki and was approved by the Ethical Committeethe newly synthesized collagen to be incorporated into
the fibrillar matrix. Both PICP and intact PINP may have of Linko¨ping University Hospital (Linko¨ping, Sweden).
added utility in renal failure since their clearance from
Biochemical determinationsthe circulation is independent of renal function [18].
Type I collagen breakdown was assessed by measuring The routine serum analytes, creatinine, urea, phos-
phate, and calcium corrected for serum albumin weretwo serum-based markers of collagen degradation: type
I collagen carboxy-terminal telopeptide (ICTP) and determined using a Hitachi 917 analyzer (Boehringer
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Mannheim GmbH, Mannheim, Germany). Serum intact cell line, and all assays are standardized against BALP
purified from SaOS-2 cells [27, 28]. Alkphase-B is a two-parathyroid hormone (PTH) was determined by a two-
site immunoradiometric assay (IRMA; Nichols Institute, stage assay based on a single monoclonal antibody,
coated to microtiter strips, which captures BALP. InSan Juan Capistrano, CA, USA), with a reported refer-
ence interval for healthy adults of 12 to 65 ng/L [20]. the second stage, the activity of the captured BALP is
determined with a colorimetric endpoint. Results areSerum osteocalcin was determined by an in-house com-
petitive radioimmunoassay (RIA) procedure using a reported in activity units (U/L). Details of the procedure
and assay performance characteristics are described else-polyclonal antiserum raised in a rabbit against purified
bovine osteocalcin [21]. where [28–30]. Reported serum BALP reference inter-
vals with the Alkphase-B assay for healthy adults wereSerum PICP, PINP, and ICTP were determined by
RIA (Orion Diagnostica, Oulunsalo, Finland). Reported 15.0 to 41.3 U/L for men and 11.6 to 30.6 U/L for women
[28]. Tandem-R Ostase is a solid-phase, two-site IRMAreference intervals for serum PICP and PINP in healthy
adults were 38 to 202g/L and 20 to 76g/L for men and using two monoclonal antibodies directed against differ-
ent epitopes of BALP. Results are reported in mass units50 to 170 g/L and 19 to 84 g/L for women, respectively
[22, 23]. Similarly, reference intervals for serum ICTP (g/L). Details of the procedure and assay performance
characteristics are described elsewhere [31, 32]. Re-in healthy adults were 1.8 to 5.0g/L for men and women
[24]. We also used the recently developed serum Cross- ported serum BALP reference intervals with the Tan-
dem-R Ostase assay for healthy adults were 5 to 22 g/LLaps One Step enzyme-linked immunosorbent assay
(ELISA; Osteometer Biotech A/S, Herlev, Denmark), for men and women [32]. We also used Tandem-MP
Ostase, a recently reported single monoclonal antibodywhich is reported to measure degradation products of
mature cross-linked type I collagen [25]. This assay de- microplate-based enzyme immunoassay [33]. The BALP
monoclonal antibody used in this assay is reported to betects a different antigenic epitope to the ICTP assay
and relies on the presence of two cross-linked carboxy- identical to that used in the Tandem-R Ostase IRMA
[27, 33]. Reported serum BALP reference intervals withterminal telopeptide 1 chains, each bearing an octapep-
tide sequence containing a -isomerized aspartate resi- the Tandem-MP Ostase assay for healthy adults are the
same as for the Tandem-R Ostase assay (discussed pre-due. The reported serum CrossLaps levels (mean SD)
in a healthy adult female reference population were viously in this article) [32, 33].
1748  740 pmol/L in premenopausal and 2952  1325
Statistical analysispmol/L in postmenopausal women [25].
Serum total ALP activity was measured on a Hitachi All calculations were performed with the StatView 5.0
program (SAS Institute Inc., Cary, NC, USA). Nonpara-917 analyzer (Boehringer Mannheim GmbH) [26]. The
BALP isoforms B/I, B1x, B1, and B2 were determined metric statistics were used because the distributions were
not Gaussian according to the Kolmogorov-Smirnov test.by a previously described HPLC method [12, 13]. In
summary, the BALP isoforms were separated using a The Mann–Whitney test was used to test for differences
between the groups of healthy individuals and patientsgradient of 0.6 mol/L sodium acetate at pH 7.6 on a weak
anion-exchange column, SynChropak AP300 (250  4.6 with CRF and to test for sex-related differences within
the groups. The Kruskal–Wallis test was used if moremm I.D.; Eichrom Technologies, Inc./SynChrom, Inc.,
Darien, IL, USA), optimized for BALP isoform analysis than two groups were compared. To measure the associa-
tion of linear relationship, we calculated Kendall’s tau[6]. The effluent was mixed online with the substrate
solution (1.8 mmol/L p-nitrophenyl phosphate in a 0.25 rank correlation coefficient. A difference was considered
statistically significant at P  0.05 for all statistical tests.mol/L diethanolamine buffer, pH 10.1), and the ensuing
reaction took place in a packed bed postcolumn reactor
at 37C. The formed product (p-nitrophenol) was then
RESULTS
directed online through the detector set at 405 nm. The
Routine serum analytes, PTH, osteocalcin, andareas under each peak were integrated, and the total
markers of type I collagen turnoverALP activity was used to calculate the relative activity
of each of the detected BALP isoforms. The serum levels of the routine analytes were (mean
SEM): creatinine, 668  34 mol/L; urea, 18.2  0.8We also measured total serum BALP using three dif-
ferent commercially available assays: Alkphase-B from mmol/L; phosphate, 1.86  0.13 mmol/L; and calcium
corrected for serum albumin concentration, 2.57  0.05Metra Biosystems, Inc. (Mountain View, CA, USA),
Tandem-R Ostase, and Tandem-MP Ostase, both mmol/L. The mean serum PTH level was increased
(mean  SEM) to 304  78 ng/L in the CRF group. Thefrom Hybritech, Inc./Beckman Coulter (San Diego, CA,
USA). The monoclonal antibodies against BALP used serum osteocalcin reference interval by mean  2 SD
for healthy adults (N  1121), with a mean age of 53in these immunoassays were all prepared by immunizing
mice with BALP purified from the SaOS-2 osteosarcoma years (range 25 to 90 years), was30g/L. No significant
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Fig. 1. Scatter diagram showing the parathy-
roid hormone (PTH), osteocalcin, markers of
type I collagen formation (PICP and PINP),
and type I collagen degradation (ICTP and
CrossLaps) concentrations for the patient
group with CRF. Symbols are: () chronic
renal failure (CRF) patients with B1x (N 
12); () CRF patients with no detectable B1x
(N  8). The horizontal lines indicate the up-
per and lower reference limits. Note that only
the upper reference limit is shown for osteo-
calcin.
differences were found between those undergoing hemo-
dialysis and peritoneal dialysis therapy or between fe-
males and males for any of the measured routine analytes
and markers of bone turnover. Moreover, no significant
Kendall’s tau rank correlation was observed with disease
duration or dialysis duration. Of the bone turnover mark-
ers, those cleared by renal filtration (osteocalcin, ICTP,
and CrossLaps) had the highest serum levels in compari-
son with the reference intervals of healthy adults. In
particular, values for ICTP in all 20 patients were mark-
edly elevated with serum concentrations on average ten-
fold greater than the upper reference limit (Fig. 1).
BALP by commercial immunoassay kits Fig. 2. Scatter diagram showing the BALP values for the immuno-
assays Alkphase-B, Tandem-R Ostase, and Tandem-MP Ostase for theBone alkaline phosphatase values in the CRF group
patient group with CRF. Symbols are: () CRF patients with B1x (N 
were (mean  SEM) 17.3  2.9 U/L for the Alkphase-B 12); () CRF patients with no detectable B1x (N  8). The horizontal
lines indicate the upper and lower reference limits.assay, 23.1  4.8 g/L for the Tandem-R Ostase assay,
and 21.6  4.0 g/L for the Tandem-MP Ostase assay
(Fig. 2). The Kruskal–Wallis test showed no significant
BALP isoforms by HPLCdifference between the three assays. However, 17 of the
20 BALP values were in the lower quartile or below the Six ALP isoforms were separated and quantitated by
HPLC in each of the healthy adult serum samples investi-reported reference interval for the Alkphase-B assay,
gated: three BALP (B/I, B1, and B2) and three LALPbut not for either of the two other immunoassays (Fig. 2).
(L1, L2, and L3) isoforms. Total ALP and ALP isoformUsing HPLC, we analyzed the BALP isoform profiles
reference intervals by 2.5 and 97.5% for healthy adultsof the high-level calibrators from the Alkphase-B and
(N  153), with a mean age of 46 years (range 21 to 90Tandem-R Ostase immunoassay kits (Fig. 3). Both of
years), were total ALP, 1.6 to 4.1 kat/L; B/I, 0.04 tothese calibrators were found to have high activities of
0.17 kat/L; B1, 0.20 to 0.62 kat/L; B2, 0.34 to 1.69the B/I fraction (Alkphase-B 80% and Tandem-R Ostase
kat/L; B1/B2 ratio, 0.23 to 0.72; L1, 0.12 to 0.74 kat/L;
39%) in comparison with human serum, where the B/I L2, 0.36 to 0.83 kat/L; and L3, 0.10 to 0.34 kat/L. No
component has the lowest activity of all of the ALP significant differences were found between the different
isoforms (on average 4% of the total ALP activity). age decades (Kruskal–Wallis test). The median value of
Hence, it is not surprising that the B/I peak has the the B/I isoform was higher in females than in males (P
highest degree of linear relationship among the BALP 0.001, 0.09 and 0.07 kat/L, respectively). No other sex-
related differences were found.isoforms with these commercial immunoassays (Table 1).
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Fig. 3. Chromatographic BALP profiles. (A)
High BALP calibrator of the Alkphase-B assay
(140 U/L). Peaks, activities, retention times,
and peak heights, in order of elution are as
follows: B/I, 112 U/L, 4.83 min, 0.0662 ab-
sorbance units; B1, 13 U/L, 6.77 min, 0.0040
absorbance units; B2, 15 U/L, 9.92 min, 0.0022
absorbance units. (B) High BALP calibrator
of the Tandem-R Ostase assay (120 g/L).
Peaks, activities, retention times, and peak
heights in order of elution are as follows: B/I,
47 g/L, 4.87 min, 0.0505 absorbance units; B1,
24 g/L, 6.83 min, 0.0148 absorbance units;
B2, 49g/L, 9.82 min, 0.0149 absorbance units.
Table 1. Correlation coefficients between PTH and biochemical markers of bone turnover in patients with CRF
BALP isoforms by HPLC BALP by immunoassays Type I collagen markers
Total
PTH ALP B/I B1xa B1 B2 B1/B2 Alkphase-B Tandem-R Tandem-MP PICP PINP ICTP CrossLaps
Total ALP 0.07
B/I 0.25 0.51c
B1x 0.49b 0.70c 0.47b
B1 0.22 0.64e 0.57d 0.53b
B2 	0.10 0.66e 0.23 0.32 0.37b
B1/B2 0.23 	0.30 0.06 0.09 0.05 	0.57d
Alkphase-B 0.24 0.51c 0.48c 0.41 0.44c 0.38b 	0.11
Tandem-R 0.17 0.36b 0.55d 0.12 0.41b 0.30 	0.19 0.67e
Tandem-MP 0.20 0.57d 0.55d 0.42 0.48c 0.36b 	0.12 0.81e 0.63e
PICP 0.08 0.22 0.37b 0.09 0.24 0.24 	0.26 0.23 0.39b 0.20
PINP 0.20 0.39b 0.32b 0.55b 0.27 0.34b 	0.25 0.52c 0.44c 0.46c 0.34b
ICTP 0.07 0.40b 0.07 0.42 0.18 0.54d 	0.49c 0.19 0.03 0.22 0.30 0.37b
CrossLaps 0.12 0.25 0.20 0.36 0.06 0.26 	0.31 0.39b 0.18 0.45c 0.23 0.68e 0.42b
Osteocalcin 0.23 0.23 0.33b 0.33 0.17 0.17 	0.12 0.51c 0.43c 0.45c 0.35b 0.70e 0.20 0.56d
Abbreviations are in the Appendix. Patients with CRF, N  20.
a Patients with CRF expressing B1x, N  12
b P  0.05, c P  0.01, d P  0.001, and e P  0.0001, by Kendall’s tau rank correlation
The total ALP activity (mean  SEM, 4.5  0.51
kat/L) was significantly (P  0.0001) increased in CRF
patients in comparison with healthy adults, and this in-
crease was due to elevated levels of B/I (0.17  0.04
kat/L, P  0.05) and B2 (1.73  0.32 kat/L, P  0.01;
Fig. 4). Moreover, no significant difference was observed
for the B1 isoform (0.42  0.05 kat/L, P  0.54) be-
tween the CRF patients and healthy adults. No signifi-
cant differences were found for any of the BALP iso-
forms between the groups of hemodialysis and peritoneal
dialysis or between females and males within the CRF
group. Only the B1/B2 ratio showed a significant Ken-
dall’s tau rank correlation with disease duration (0.40,
P  0.02), and no significant correlation was observed
with the duration of dialysis treatment.
Fig. 4. Scatter diagram showing the total ALP and BALP isoformDetection of the BALP isoform B1x
activities for the patient group with CRF. Symbols are: () CRF patients
The additional BALP isoform B1x was detected in with B1x (N  12); () CRF patients with no detectable B1x (N  8).
The horizontal lines indicate the upper and lower reference limits.serum from 12 (60%) of the CRF patients. The B1x
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Table 2. Comparison between CRF patients displaying the B1x BALP isoform (B1x
) and patients with no detectable B1x (B1x	)
B1x
 B1x	 P valuea
Total ALP lkat/L 3.2 (2.1–6.5) 4.8 (2.4–10.0) NS (0.08)
B/I lkat/L 0.08 (0.05–0.32) 0.22 (0.06–0.80) 0.05
B1 lkat/L 0.32 (0.16–0.97) 0.42 (0.32–1.06) 0.05
B2 lkat/L 1.24 (0.56–3.36) 1.60 (0.43–6.01) NS (0.25)
B1/B2 ratio 0.28 (0.17–0.48) 0.27 (0.10–0.74) NS (0.76)
Alkphase-B U/L 11.2 (7.9–37.0) 15.4 (11.2–56.8) 0.05
Tandem-R lg/L 12.0 (5.4–52.0) 23.4 (13.2–88.0) 0.01
Tandem-MP lg/L 13.4 (7.3–47.2) 20.5 (10.5–76.0) NS (0.054)
PTH ng/L 183 (3.0–626) 244 (42–1450) NS (0.25)
Osteocalcin lg/L 58 (9.5–503) 122 (9.7–976) NS (0.25)
PICP lg/L 152 (76–272) 226 (139–446) 0.05
PINP lg/L 50 (18–146) 64 (17–536) NS (0.40)
ICTP lg/L 46 (28–120) 48 (17–88) NS (0.62)
CrossLaps pmol/L 12550 (2909–24000) 9818 (2484–42500) NS (0.93)
Values are given as median, with the minimum and maximum values in parentheses. NS is not significant. Other abbreviations are listed in the Appendix.
a Mann–Whitney test between CRF patients displaying the B1x BALP isoform (B1x
, N  12) and CRF patients with no detectable B1x (B1x	, N  8)
isoform has previously been detected in extracts of hu- type I collagen turnover in CRF patients [3, 34, 35], al-
man bone but has not been resolved in serum from though the utility of these makers has been doubted [36].
healthy individuals. The original observation of the B1x The usefulness of PICP in assessing bone formation has
peak, including a chromatographic profile and character- been considered in hemodialysis patients with renal bone
ization of this bone ALP peak, is reported elsewhere disease by Hamdy et al, who reported significant correla-
[14]. The B1x isoform did not show a significant correla- tions between histologically determined bone formation
tion with any of the three immunoassays, and moreover, rates and the bone formation markers PICP, total ALP,
patients with detectable B1x were not those expressing and osteocalcin [34]. Furthermore, they deduced that
the highest levels of BALP measured by the immuno- formation markers within reference intervals for healthy
assays (Fig. 2). Notably, B1x was the only biochemical individuals were associated with normal bone formation
marker of bone turnover that had a significant correla- rates, which suggests that the majority of our CRF pa-
tion with PTH (0.49, P  0.05; Table 1). tients with formation marker levels within the reference
Dividing the CRF patients into two groups based on limits could have a normal bone formation rate.
those patients displaying the B1x BALP isoform (B1x
, Circulating levels of osteocalcin, ICTP, and Cross-
N 12) and patients with no detectable B1x (B1x	, N8) Laps, which are cleared by the kidney, were elevated in
revealed several differences. Patients with B1x were older, the majority of our patients. The interpretation of serum
with a median age of 71 years (range 51 to 87 years), osteocalcin in dialysis patients has been proved difficult,
versus 54 years (range 33 to 79 years) of age (P  0.05), since many of the immunoassays employ polyclonal anti-
and had, in general, lower median levels of the markers of bodies with broad specificities and the ability to detect
bone turnover (Table 2 and Figs. 1, 2, and 4). In particular, several immunologic fragments, including the intact mol-
median levels of the B/I and B1 isoforms and BALP, ecule [37, 38]. Thus, reduced renal clearance inevitably
measured using the Alkphase-B and Tandem-R Ostase leads to elevated osteocalcin levels, although the effec-
assay kits, and PICP levels were significantly lower in those tiveness of the various dialysis techniques to remove osteo-
patients with B1x. However, no significant differences calcin, as well as ICTP and CrossLaps, is uncertain. Perito-
were found for creatinine, urea, phosphate, corrected neal dialysis has been shown to reduce serum osteocalcin
calcium, PTH, dialysis duration, or disease duration. in children with end-stage renal disease [39]. Similarly,
serum levels of pyridinoline cross-links are reduced by
DISCUSSION hemodialysis, indicating clearance of these cross-links
and, by inference, their cross-linked peptides from theWe have investigated circulating markers of bone
circulation by this technique [40]. The clinical usefulnessturnover, in particular the isoforms of BALP, in a group
of osteocalcin and type I collagen telopeptides in as-of CRF patients managed by either peritoneal dialysis or
sessing bone turnover in CRF is questionable, althoughhemodialysis. To our knowledge, our study provides the
relative osteocalcin levels have been considered to distin-first analysis and comparison of BALP isoforms measured
guish low from high-turnover bone disease [41–43].by HPLC and commercial BALP immunoassays, in addi-
Parathyroid hormone was analyzed using a commer-tion to other serum markers of type I collagen turnover
cial assay originally reported to detect the intact (1-84used in the assessment of bone metabolism in CRF.
Previous studies have reported elevated markers of PTH) circulating molecule. However, it has recently
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been demonstrated that a fragment (most likely 7-84 However, the presence of B1x in these sera cannot be
excluded since its intermediate retention time, and possi-PTH) interferes significantly with this assay [44, 45].
Thus, the PTH values reported in our study might be ble lower activity than either of the B/I and B1 peaks,
may confound its detection [14].higher than the true circulating levels of intact 1-84 PTH
because of the presence of this amino-terminal truncated The BALP isoform B1x could be related to secondary
hyperparathyroidism, which is common in dialysis pa-fragment of inactive 7-84 PTH. In addition to the more
obvious methodological aspects, this finding also will tients, since B1x was the only marker of bone turnover
that showed a significant association with PTH. Alterna-presumably have implications for the treatment of renal
bone disease. tively, B1x may indicate low-turnover adynamic bone
disease as those patients expressing B1x had lower me-No significant differences were observed between the
three different BALP immunoassays. As shown in the dian values for 12 of the measured analytes (Table 2),
which may reflect suppressed osteoblast activity. It ischromatographic profiles of the commercial calibrators
(Fig. 3), these kits are calibrated to a large degree against unlikely that B1x is related to the other type of low-
turnover bone disease in renal bone disease, that is, os-the B/I fraction. In serum from healthy subjects, B/I has
a lower activity than either the B1 and B2 isoforms and teomalacia, since this is usually accompanied by in-
creased ALP levels [5]. In general, this was not the caserepresents, on average, only 4% of the total ALP activity
measured. Some differences have been reported between for the CRF patients with B1x. Further investigations of
patients with primary and secondary hyperparathyroid-these BALP immunoassays in groups of patients that
express different ratios of these BALP isoforms, which ism and histologically defined bone disease are needed
before these findings are adequately explained.could be explained by differences between the antibodies
used in these immunoassays [46–48]. A worldwide work- In summary, our data show that there are selective
differences between the BALP isoforms in patients withshop facilitated by the International Society of Onco-
developmental Biology and Medicine (ISOBM) has re- CRF in comparison with healthy adults. The increased
total ALP activity was largely due to increased activitiescently begun to evaluate the properties, specificity, and
target epitopes of all available antibodies to BALP. The of the BALP isoforms B/I and B2 in several patients.
The BALP isoform B1x was detected in 60% of the pa-results of this workshop may provide useful information
about the nature and location of the epitopes, including tients, but was not detected in the control group of healthy
new information about the different BALP isoforms [ab- individuals. B1x did not show a significant correlation
stract; A¨rlestig et al, Tumor Biol 21(Suppl 1):87, 2000]. with any of the three BALP immunoassays; however, it
In addition to differences between the BALP isoforms was the only biochemical marker of bone turnover that
patterns in clinical situations [6, 12, 15–17], we also iden- had a significant correlation with PTH. Interestingly, the
tified bone compartment-specific differences. Cortical immunoassay calibrators had relatively high activities of
bone was found to have approximately twofold higher the B/I fraction (39 to 80%) in comparison with serum
activity of B1 compared with B2, whereas trabecular from healthy individuals (4%). The three commercially
bone had approximately twofold higher activity of B2 available BALP immunoassays are comparable with
compared with B1 [14]. The detection of B1x in some each other, but are unable to distinguish the BALP iso-
patients with renal disease may be related to differences form specific differences in this set of patients with CRF.
in the metabolism of different bone compartments or, Future investigations should include immunoassay anal-
more specifically, the effects of PTH on osteoblast popu- ysis of purified BALP isoform fractions in order to char-
lations within these compartments. Generalized thinning acterize the specificity of these antibodies to the different
of cortical bone due to increased net endocortical resorp- BALP isoforms. Furthermore, the BALP isoform B1x
tion has recently been reported in a group of patients should be evaluated as a potential marker of low turn-
with histologically classified osteitis fibrosa and osteoma- over adynamic bone disease accurately classified by bone
lacia [49]. The influence of PTH and site-specific differ- histomorphometry.
ences in bone turnover, and their possible effect on the
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